Company
AEON Biopharma
Advancing access to therapeutic botulinum toxins through biosimilarity
Also known as AEON Biopharma, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Customers
- patients, providers, and payers
- Legal name
- AEON Biopharma, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
At AEON Biopharma, we focus exclusively on expanding the therapeutic use of botulinum toxins in patients with debilitating neuromuscular disorders. Our lead product, ABP-450, is being developed as a branded biosimilar to BOTOX, designed to expand access to high-quality therapeutic neurotoxin treatments and deliver meaningful value across the healthcare system.
Funding snapshot
- Total raised
- $197MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $30M2022-07-29
Funding rounds
- Round, 2022
- $30M2022-07-29, SEC form D sold, 1 investor
- Round, 2021
- $24.5M2021-12-08, SEC form D sold, 1 investor
- Round, 2020
- $30M2020-08-25, SEC form D sold, 1 investor
- Round, 2016
- $5.5M2016-07-26, SEC form D sold, 5 investors
- Round, 2015
- $80.1M2015-11-10, SEC form D sold, 28 investors
- Round, 2015
- $27M2015-01-14, SEC form D sold, 5 investors
Products
- Other
- ABP-450
Loading relationship preview